Slide 1: NightHawk Biosciences Investor Presentation - December 2023
NightHawk Biosciences A rapidly growing, highly scalable biomanufacturing Contract Development & Manufacturing Organization Investor Presentation - December 2023 NYSE: NHWK
Slide 2: Forward-looking statements
This presentation includes statements that are, or may be deemed, “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, includin
Slide 3: Investment Highlights
Investment Highlights Growing demand for Contract Development & Manufacturing Organization (CDMO) services and significant shortage of dedicated clinical-scale manufacturing capacity within the industry Scorpius began 2023 with $3M of signed manufacturing contracts, which has grown to over $20M
Slide 4: About NightHawk
• NightHawk Biosciences, through its Scorpius BioManufacturing subsidiary, is an integrated CDMO focused on rapidly advancing biologic programs through the clinic • With end-to-end capabilities from discovery to limited-scale commercial production, we provide a broad array of R&D, analytical testing
Slide 5: Scorpius Leadership Team
Joe Payne VP, Quality & Regulatory 20+ Years Of Experience Alcami, Tergus, Teva SCORPIUS LEADERSHIP TEAM Brian O’Mara VP, Process Sciences 20+ Years Of Experience Ambrx, Bristol-Myers Squibb, Genencor, Wyeth Lise Barley-Maloney Sr. Dir., Program Management 30+ Years Of Experience FUJIFILM, KBI Bioph
Slide 6: Scorpius Snapshot
Scorpius Snapshot Clinical-scale biomanufacturing in San Antonio, TX located in the heart of a thriving innovation district Highly skilled scientific leadership team US-sourced supply chain In-house process development and analytical services
Slide 7: San Antonio Facility Overview
San Antonio Facility Overview • ~2,000 sq. ft. (185 m2) of analytical support and QC testing space • ~2,000 sq. ft. (185 m2) process development lab • ~5,400 sq. ft. (500 m2) of cGMP cleanroom manufacturing space (mammalian and cell therapy) • ~3,200 sq. ft. (300 m2) of cGMP cleanroom manufacturing
Slide 8: Supported Drug Modalities
SUPPORTED DRUG MODALITIES Phase-Appropriate Process Development Clinical-Scale Manufacturing Commercial-Scale Manufacturing Mammalian Cell Culture • Antibody Production • Monoclonals, Bi-Specifics • Recombinant Therapeutic Proteins • Allogeneic Cell Therapy • Cells, Exosomes, Secretome Microbial Fer
Slide 9: Integrated Bioanalysis Support for Product's Lifecycle
Comprehensive bioassay and bioanalytical capabilities allow for seamless progression of therapeutic candidates throughout their lifecycle INTEGRATED BIOANALYSIS SUPPORT FOR PRODUCT’S LIFECYCLE
Slide 10: Summary
Summary Growing demand for Contract Development & Manufacturing Organization (CDMO) services and significant shortage of dedicated clinical-scale manufacturing capacity within the industry Scorpius began 2023 with $3M of signed manufacturing contracts, which has grown to over $20M in signed manu